Tuberculosis (TB) was announced as a global emergency in 1993. There was an alarming
counter attack of TB worldwide. However, when it was known that TB can be cured …

This paper describes an action framework for countries with low tuberculosis (TB) incidence
(< 100 TB cases per million population) that are striving for TB elimination. The framework …

A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium
tuberculosis is required to accelerate the development of rapid drug susceptibility testing …

Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Bedaquiline, a diarylquinoline, improved cure rates when added to a multidrug-resistant
tuberculosis (MDR-TB) treatment regimen in a previous placebo-controlled, phase 2 trial …

Drug-resistant tuberculosis (DR-TB), including multi-and extensively drug-resistant TB, is
posing a significant challenge to effective treatment and TB control worldwide. New progress …

Background New antituberculosis regimens are urgently needed to shorten tuberculosis
treatment. Following on from favourable assessment in a 2 week study, we investigated a …

Extensively drug-resistant tuberculosis is a burgeoning global health crisis mainly affecting
economically active young adults, and has high mortality irrespective of HIV status. In some …

About 1· 3 million people died of tuberculosis in 2012, despite availability of effective drug
treatment. Barriers to improvements in outcomes include long treatment duration (resulting …